Data from Peking University Cancer Hospital and Institute Provide New Insights into Alveolar Soft Part Sarcoma (Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial).

A recent study conducted at Peking University Cancer Hospital and Institute in Beijing, China, explored the efficacy and safety of combining anlotinib and TQB2450 in patients with Alveolar Soft Part Sarcoma (ASPS). The study enrolled 29 patients, with 82.1% achieving an objective response, including complete and partial responses. The combination treatment was found to be effective and tolerable, with potential prognostic biomarkers identified for further investigation. The findings were published in Clinical Cancer Research by the American Association for Cancer Research. [Extracted from the article]